864 related articles for article (PubMed ID: 10857839)
1. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
2. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
3. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
5. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
7. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
8. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
[TBL] [Abstract][Full Text] [Related]
9. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
10. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L
Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466
[TBL] [Abstract][Full Text] [Related]
11. Systemic beta-blocker therapy and brimonidine and timolol.
Coulibaly R
Ophthalmology; 2001 Aug; 108(8):1368. PubMed ID: 11470677
[No Abstract] [Full Text] [Related]
12. Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Simmons ST;
Clin Ther; 2001 Apr; 23(4):604-19. PubMed ID: 11354394
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
14. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
[TBL] [Abstract][Full Text] [Related]
18. A short term study of the additive effect of timolol and brimonidine on intraocular pressure.
Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A
Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886
[TBL] [Abstract][Full Text] [Related]
19. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Craven ER; Walters TR; Williams R; Chou C; Cheetham JK; Schiffman R;
J Ocul Pharmacol Ther; 2005 Aug; 21(4):337-48. PubMed ID: 16117698
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
